Developing an AI-Based Predictive Tool for Patients with Stage IV NSCLC Receiving Immunotherapy or Chemo-Immunotherapy

What this Trial Is About

Researchers are developing an artificial intelligence tool to predict how patients with metastatic non-small cell lung cancer NSCLC will respond to treatments. This study focuses on patients treated with either immunotherapy alone or chemo-immunotherapy combinations as first-line treatment. The goal is to identify patients who may not respond well, experience severe toxicities, or survive longer than average, to help personalize their care and follow-up plans. The study observes two groups of patients those receiving immunotherapy alone and those receiving chemo-immunotherapy. Data will be collected both retrospectively and prospectively from clinical, laboratory, radiological, and pathological sources at specific timepoints. This information will be analyzed to build and continuously update a predictive score that weighs the importance of various factors over time. Participants will have their disease progression, immune-related lung toxicity, and survival monitored over time. Early disease progression will be assessed within 8 to 12 weeks after treatment start, lung toxicity will be tracked up to 96 months, and survival outcomes will be evaluated at a 3-year mark. The study aims to use this data to improve individual patient management and treatment decisions.

AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer